Sarepta Therapeutics Inc (NASDAQ:SRPT) & Applied Materials, Inc. (NASDAQ:AMAT)
Dec 18 2016 by Johnny Bowman
Cubist Systematic Strategies Ltd Liability Company holds 274 shares or 0% of its portfolio. They now have a United States dollars 32 price target on the stock. For the prior quarter revenue for the stock hit $0, with EPS at -$1.35. Alliancebernstein L P has invested 0% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT).
Investment analysts at Wedbush reduced their Q3 2017 earnings per share estimates for Stemline Therapeutics in a report released on Tuesday. There were earnings of $-1.18 per share. Equities research analysts expect that Sarepta Therapeutics Inc. will post ($4.70) earnings per share for the current fiscal year. "(SRPT)" was published by Marea Informative and is the propert of of Marea Informative. If you are viewing this story on another site, it was illegally stolen and republished in violation of USA & worldwide copyright & trademark law. RBC Capital Markets now has an outperform rating on the stock.
Stock market analysts and brokers have recently amended their target prices on shares of Sarepta Therapeutics, Inc. Oppenheimer Holdings Inc. reiterated an "outperform" rating and issued a $76.00 price target on shares of Sarepta Therapeutics in a research report on Monday, October 17th. About 2.96M shares traded hands or 29.82% up from the average.
Sarepta Therapeutics (NASDAQ:SRPT) had its target bumped down to $98.00 by RBC Capital in an issued report announced 12/16/2016. (NYSE:HP) now has mean rating of 3.00 while 0 analysts have commented the shares as "BUY", 0 recommended as "OUTPERFORM" and 0 commented as "HOLD". Wall Street analysts tap into their deep knowledge of the company to help calculate future stock movement. (NASDAQ:SRPT) granted equity awards on November 30, 2016, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2014 Employment Commencement Incentive Plan, as a material inducement to employment to seven individuals hired by Sarepta in November 2016. As of the most recent bid at the time of writing, Stemline Therapeutics, Inc. shares are trading -21.92% away from the 52-week high mark of 14.60 and +193.81% off the 52-week bottom of 3.88. The company has a total market capitalization of $1.57 billion. The stock's price moved up its 200-day moving average of $28.03.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has a mean revenue estimate for the ongoing quarter ending Dec 16 of $26.51M, according to 13 analysts. Vanguard Group Inc. now owns 3,105,816 shares of the company's stock valued at $59,227,000 after buying an additional 161,790 shares during the period.
In order to arrive at a price target, analysts and investors alike use various metrics to determine where the stock might be headed. 60 funds bought stakes while 48 increased positions. Following the transaction, the chief executive officer now directly owns 89,983 shares of the company's stock, valued at $4,499,150. Finally, BlackRock Institutional Trust Company N.A. increased its stake in Sarepta Therapeutics by 5.6% in the third quarter. They now have a Dollars 76 price target on the stock. Howton David T sold $465,200 worth of stock or 9,304 shares. A SVP, Regulatory Affairs & Qual in the company, Ruff Shamim, on Thursday September 22, 2016 collected $438,660 from the sale of 7,311 shares at a per-share price of $50.08. The stock is presently trading up its SMA-50 of $30.57. They now have a United States dollars 41 price target on the stock. The disclosure for this sale can be found here.
Sarepta Therapeutics, Inc.is a biopharmaceutical company. The Firm is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.